



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

ZANUBRUTINIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ZANUBRUTINIB	BRUKINSA	46212		GPI-10 (2153409500)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of mantle cell lymphoma (MCL) and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient has received at least ONE prior therapy for mantle cell lymphoma

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #4 per day.**
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **ZANUBRUTINIB (Brukinsa)** requires the following rule(s) be met for approval:

- A. You have a diagnosis of mantle cell lymphoma (type of white blood cell cancer)
- B. You are 18 years of age or older
- C. You have previously received at least ONE prior therapy for mantle cell lymphoma

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Brukinsa.

REFERENCES

- Brukinsa [Prescribing Information]. San Mateo, CA: BeiGene USA, Inc.; November 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 04/01/20

Created: 02/20

Client Approval: 02/20

P&T Approval: 1/20